UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation. Fair value range: low $230, high $450, with mid-point at $340.
Ten raport nie został jeszcze przetłumaczony. Odśwież za kilka minut, gdy kolejka tłumaczeń go przetworzy.
§1 Podsumowanie wykonawcze
UNH offers unmatched scale in healthcare but currently faces acute near-term margin pressure.
Valuation models heavily cap aggressive extrapolations, yielding a grounded $339.99 fair value.
The current price of $378.07 embeds growth expectations that risk a multiple de-rating.
Fair value
$340
Margin of safety
-11.2%
Confidence
88/100
Moat
9/10
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
$378.07Price
Low $230.47
Mid $339.99
High $449.63
UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation.
Cycle upside
Favorable regulatory environments, stable utilization rates, and rapid adoption of value-based care.
Reverse DCF for UNH (UNH) backs out the revenue or earnings growth rate the current share price implies, holding terminal value, margin, and discount-rate assumptions constant.
We compare the implied rate to our own forecast deceleration curve and to the historical five-year actual. When the implied rate exceeds the realistic ceiling, the price is pricing in optimism the business has not yet demonstrated.
Reverse DCF uses cost of equity (Ke), not WACC, to stay consistent with the EPS-based forward valuation models. Ke is derived from CAPM with adjusted beta; the strict and moderate variants are documented in the assumption ledger.
When the implied growth rate is below our forecast, the market is underpricing the business; when it is above, the market is overpricing. The reverse-DCF read is one of four lenses that feed the composite fair-value range and the rating band.
FAQ
UNH — frequently asked questions
Based on our latest analysis, UNH screens modestly overvalued. The current price is $378 versus a composite fair-value midpoint of $340 (range $230–$450), which implies roughly 10.1% downside to the midpoint.
Our composite fair-value range for UNH is $230–$450, with a midpoint of $340. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for UNH's archetype.
Our current rating for UNH is Reduce with a confidence score of 88/100. We rate UNH a Reduce (or Hold for strictly long-term, tax-sensitive accounts). The heavily penalized $339.99 midpoint reflects near-term operational realities. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for UNH are: Permanent MA Rate Cuts; Runaway Medical Inflation; Antitrust Optum Breakup. The single biggest risk is Permanent MA Rate Cuts: Regulatory agencies structurally enforce severe Medicare Advantage rate cuts, permanently destroying UNH margin profiles.
Our current rating for UNH is Reduce, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($230–$450) versus the current price of $378.
UNH is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for UNH.